MX2011011338A - Composiciones y metodos de uso para anticuerpos terapeuticos especificos para la subunidad beta1 del receptor de il-12. - Google Patents
Composiciones y metodos de uso para anticuerpos terapeuticos especificos para la subunidad beta1 del receptor de il-12.Info
- Publication number
- MX2011011338A MX2011011338A MX2011011338A MX2011011338A MX2011011338A MX 2011011338 A MX2011011338 A MX 2011011338A MX 2011011338 A MX2011011338 A MX 2011011338A MX 2011011338 A MX2011011338 A MX 2011011338A MX 2011011338 A MX2011011338 A MX 2011011338A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- receptore
- composition
- chain
- antibodies specific
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Abstract
La presente invención se refiere a anticuerpos que se enlazan específicamente con el IL12Rß1, la cadena de transducción sin señal del receptor de 1L12 heterodimérico (junto con la cadena de IL12Rß2), así como el receptor de lL23 (junto con la cadena de IL23Ra). La invención más específicamente se refiere a anticuerpos específicos que son antagonistas de los receptores de Ll12 e 1L23 capaces de inhibir la producción de IFNy inducida por IL12/IL18 de las células-T, y a composiciones y a métodos de uso para estos anticuerpos, con el fin de tratar los trastornos patológicos que se puedan tratar mediante la inhibición de la producción de lFNy, tales como artritis reumatoide, soriasis, o enfermedades inflamatorias del intestino, u otros trastornos autoinmunes e inflamatorios.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16517709P | 2009-04-27 | 2009-04-27 | |
PCT/EP2010/054093 WO2010112458A1 (en) | 2009-03-31 | 2010-03-29 | Composition and methods of use for therapeutic antibodies specific for the il-12 receptore betal subunit |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2011011338A true MX2011011338A (es) | 2012-04-19 |
Family
ID=42174564
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2011011338A MX2011011338A (es) | 2009-04-27 | 2010-03-29 | Composiciones y metodos de uso para anticuerpos terapeuticos especificos para la subunidad beta1 del receptor de il-12. |
Country Status (11)
Country | Link |
---|---|
US (2) | US8715657B2 (es) |
EP (1) | EP2424894A1 (es) |
JP (1) | JP2012524524A (es) |
KR (1) | KR20120057563A (es) |
CN (1) | CN102414223A (es) |
AU (1) | AU2010230311B9 (es) |
BR (1) | BRPI1016055A2 (es) |
CA (1) | CA2759942A1 (es) |
EA (1) | EA201101572A1 (es) |
MX (1) | MX2011011338A (es) |
WO (1) | WO2010112458A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI1016055A2 (pt) * | 2009-04-27 | 2016-05-10 | Novartis Ag | composição e métodos de uso para anticorpos terapêuticos específicos para a subunidade beta i do receptor de il-12 |
BR112012019881A2 (pt) | 2010-02-18 | 2017-06-27 | Bristol Myers Squibb Co | proteínas de domínio estrutural baseadas na fibronectina que ligam-se à il-23 |
CN103154037A (zh) | 2010-10-05 | 2013-06-12 | 诺瓦提斯公司 | 抗IL12Rβ1抗体及它们在治疗自身免疫病和炎性疾病中的用途 |
CN103275222B (zh) * | 2013-05-15 | 2014-04-16 | 中山康方生物医药有限公司 | 一种阻断白介素12 p40功能的单克隆抗体及其编码基因和应用 |
WO2016102641A1 (en) * | 2014-12-24 | 2016-06-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of acute exacerbations of chronic obstructive pulmonary disease |
KR101873499B1 (ko) * | 2015-02-10 | 2018-07-03 | 주식회사 원메디칼 | 혈관 질환 진단용 바이오 마커 및 이의 용도 |
CN109810947B (zh) * | 2019-01-18 | 2021-06-11 | 北京贝来生物科技有限公司 | 一种抑制Th17细胞活化的间充质干细胞及其制备方法和应用 |
WO2023077091A1 (en) * | 2021-10-28 | 2023-05-04 | Abbvie Inc. | Anti-amyloid beta antibodies and methods of using the same |
WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
Family Cites Families (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5084413A (en) | 1986-04-15 | 1992-01-28 | Matsushita Electric Industrial Co., Ltd. | Method for filling contact hole |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
JPH02500329A (ja) | 1987-05-21 | 1990-02-08 | クリエイテイブ・バイオマリキユールズ・インコーポレーテツド | ターゲット化多機能蛋白質 |
US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
WO1991010741A1 (en) | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
ES2227512T3 (es) | 1991-12-02 | 2005-04-01 | Medical Research Council | Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago. |
CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
WO1993022332A2 (en) | 1992-04-24 | 1993-11-11 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
DK1087013T3 (da) | 1992-08-21 | 2009-05-11 | Univ Bruxelles | Immunoglobuliner uden lette kæder |
CA2161351C (en) | 1993-04-26 | 2010-12-21 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
US6046012A (en) * | 1993-07-19 | 2000-04-04 | Hoffmann-La Roche Inc. | Antibody to IL-12 receptor |
EP0638644A1 (en) * | 1993-07-19 | 1995-02-15 | F. Hoffmann-La Roche Ag | Receptors of interleukin-12 and antibodies |
SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
US5853721A (en) * | 1995-01-31 | 1998-12-29 | Hoffmann-La Roche Inc. | Antibody to interleukin-12 receptor |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
EP1724282B1 (en) | 1997-05-21 | 2013-05-15 | Merck Patent GmbH | Method for the production of non-immunogenic proteins |
DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
ES2694002T3 (es) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polipéptido que comprende una región Fc de IgG1 humana variante |
PT1914244E (pt) | 1999-04-09 | 2013-07-26 | Kyowa Hakko Kirin Co Ltd | Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico |
DE19932688B4 (de) | 1999-07-13 | 2009-10-08 | Scil Proteins Gmbh | Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen |
EP1990409A3 (en) | 1999-07-20 | 2011-05-18 | MorphoSys AG | Bacteriophage |
EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
SK287984B6 (sk) * | 2000-05-10 | 2012-08-06 | Schering Corporation | Substantially pure or recombinant polypeptide, nucleic acid, host cell, method for the preparation of polypeptide, binding compound, kit, composition comprising an antibody and use thereof |
CA2441903C (en) | 2000-05-26 | 2012-07-31 | National Research Council Of Canada | Single-domain brain-targeting antibody fragments derived from llama antibodies |
DE60139720D1 (de) | 2000-06-28 | 2009-10-08 | Glycofi Inc | Verfahren für die Herstellung modifizierter Glykoproteine |
US20020025317A1 (en) * | 2000-07-20 | 2002-02-28 | Schering Ag | Bispecific monoclonal antibodies to IL-12 and IL-18 |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
ATE378403T1 (de) | 2000-11-30 | 2007-11-15 | Medarex Inc | Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern |
WO2002092780A2 (en) | 2001-05-17 | 2002-11-21 | Diversa Corporation | Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof |
EP1443961B1 (en) | 2001-10-25 | 2009-05-06 | Genentech, Inc. | Glycoprotein compositions |
WO2003074679A2 (en) | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
US6698767B2 (en) | 2002-03-11 | 2004-03-02 | Ford Global Technologies, Llc | Adjustable suspension stabilizer bar |
DK2345671T3 (en) * | 2002-09-27 | 2016-02-15 | Xencor Inc | Optimized Fc variants and methods for their formation |
AU2003277828B2 (en) | 2002-10-29 | 2009-06-04 | Anaphore, Inc. | Trimeric binding proteins for trimeric cytokines |
DE10324447A1 (de) | 2003-05-28 | 2004-12-30 | Scil Proteins Gmbh | Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin |
CA2553692C (en) | 2004-01-20 | 2014-10-07 | Kalobios, Inc. | Antibody specificity transfer using minimal essential binding determinants |
KR20070038453A (ko) * | 2004-04-16 | 2007-04-10 | 마크로제닉스, 인크. | FcγRIIB-특이적 항체 및 그의 사용 방법 |
BRPI1016055A2 (pt) * | 2009-04-27 | 2016-05-10 | Novartis Ag | composição e métodos de uso para anticorpos terapêuticos específicos para a subunidade beta i do receptor de il-12 |
-
2010
- 2010-03-29 BR BRPI1016055A patent/BRPI1016055A2/pt not_active IP Right Cessation
- 2010-03-29 JP JP2012502617A patent/JP2012524524A/ja not_active Ceased
- 2010-03-29 MX MX2011011338A patent/MX2011011338A/es not_active Application Discontinuation
- 2010-03-29 WO PCT/EP2010/054093 patent/WO2010112458A1/en active Application Filing
- 2010-03-29 KR KR1020117025295A patent/KR20120057563A/ko unknown
- 2010-03-29 US US13/265,346 patent/US8715657B2/en active Active
- 2010-03-29 CA CA2759942A patent/CA2759942A1/en not_active Abandoned
- 2010-03-29 EP EP10711067A patent/EP2424894A1/en not_active Withdrawn
- 2010-03-29 CN CN2010800186481A patent/CN102414223A/zh active Pending
- 2010-03-29 AU AU2010230311A patent/AU2010230311B9/en not_active Ceased
- 2010-03-29 EA EA201101572A patent/EA201101572A1/ru unknown
-
2014
- 2014-03-20 US US14/220,166 patent/US20140248265A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US8715657B2 (en) | 2014-05-06 |
US20120034231A1 (en) | 2012-02-09 |
AU2010230311B2 (en) | 2012-08-16 |
US20140248265A1 (en) | 2014-09-04 |
BRPI1016055A2 (pt) | 2016-05-10 |
AU2010230311A1 (en) | 2011-10-13 |
EP2424894A1 (en) | 2012-03-07 |
JP2012524524A (ja) | 2012-10-18 |
CA2759942A1 (en) | 2010-10-07 |
WO2010112458A1 (en) | 2010-10-07 |
AU2010230311B9 (en) | 2012-09-20 |
CN102414223A (zh) | 2012-04-11 |
EA201101572A1 (ru) | 2012-05-30 |
KR20120057563A (ko) | 2012-06-05 |
WO2010112458A8 (en) | 2012-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2011011338A (es) | Composiciones y metodos de uso para anticuerpos terapeuticos especificos para la subunidad beta1 del receptor de il-12. | |
PH12015502575B1 (en) | Piperidin-4-yl azetidine derivatives as jak1 inhibitors | |
JO3149B1 (ar) | تراكيب وطرق إستعمال للأجسام المضادة العلاجية | |
GB0906579D0 (en) | Pharmaceuticals, compositions and methods of making and using the same | |
EA200970765A1 (ru) | 2-аминопиримидиновые модуляторы рецептора hгистамина | |
IL250832B (en) | A mixture of beta-glycosylceramide and beta-lactosylceramide for use in the treatment of colitis | |
MX2019007492A (es) | Composiciones de celulas t deficientes del receptor de celulas t. | |
WO2013033626A3 (en) | Nkp30 receptor targeted therapeutics | |
EA201100524A1 (ru) | Азаиндазолы в качестве антагонистов рецептора ccr1 | |
MX2011009412A (es) | Nuevos agentes anti-inflamatorios. | |
MX2019008122A (es) | Derivados de aminas heterociclicas que inhiben la transduccion de se?al mediada por cinasa asociada con el receptor de interleucina-1. | |
MX337590B (es) | Anticuerpos anti il-6 humanos, con semivida in vivo prolongada y su uso en el tratamiento de oncologia, enfermedades autoinmunes y enfermedades inflamatorias. | |
MX2009009079A (es) | Anticuerpos anti-il-23p19 de ingenieria. | |
MX2009009080A (es) | Anticuerpos anti-interleucina-23p19 manipulados por ingenieria genetica. | |
MX2013012472A (es) | Metodo y composiciones que utilizan inhibidores de pde4 para el tratamiento y manejo de enfermedades autoinmunes e inflamatorias. | |
MX2009009283A (es) | Anticuerpos anti-interleuquina -23r de ingenieria. | |
WO2012033987A3 (en) | Anti-human folate receptor beta antibodies and methods of use | |
EA201170005A1 (ru) | Диаминопиридиновые, пиримидиновые и пиридазиновые модуляторы гистаминового рецептора h | |
CO6341571A2 (es) | Composiciones y metodos de uso para anticuerpos terapeuticos | |
WO2009108635A3 (en) | Novel compositions for treatment of diseases related to activated lymphocytes | |
EA200901047A1 (ru) | Способ улучшения осветления в смесительном реакторе и смесительный реактор | |
TN2010000599A1 (en) | Compositions and methods of use for therapeutic antiodies | |
UA110108C2 (xx) | Азетидинові похідні піперидин-4-ілу як інгібітори jak1 | |
MY198316A (en) | Piperidin-4-YL Azetidine Derivatives as JAK1 Inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |